Lupin Risks First US Xarelto Generic Launch After PTAB Knocked Out Key Patent
Bayer Has Appealed PTAB’s 2023 Decision On ‘310 Patent; Other Action Stayed Pending Result
Lupin has moved quickly to begin rolling out the first generic version of the blockbuster blood thinner Xarelto in the US, despite continued legal action over a patent expiring in 2039.
